NASDAQ:FOLD - Amicus Therapeutics Stock Price, Price Target & More

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.08. The biopharmaceutical company had revenue of $16.70 million for the quarter, compared to analyst estimates of $16.78 million. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. View Amicus Therapeutics' Earnings History.

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Amicus Therapeutics.

7 brokerages have issued twelve-month target prices for Amicus Therapeutics' stock. Their forecasts range from $15.00 to $24.00. On average, they expect Amicus Therapeutics' share price to reach $19.50 in the next year. View Analyst Ratings for Amicus Therapeutics.

Amicus Therapeutics saw a increase in short interest in May. As of May 31st, there was short interest totalling 28,434,123 shares, an increase of 3.1% from the May 15th total of 29,349,145 shares. Based on an average daily trading volume, of 3,293,480 shares, the short-interest ratio is presently 8.6 days. Approximately 15.5% of the company's stock are short sold. View Amicus Therapeutics' Current Options Chain.

Some companies that are related to Amicus Therapeutics include Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), Alkermes (ALKS), SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT) and Ionis Pharmaceuticals (IONS).

Media stories about FOLD stock have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amicus Therapeutics earned a coverage optimism score of 0.14 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.71 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Amicus Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.03%), Redmile Group LLC (5.70%), Palo Alto Investors LP (3.26%), Franklin Resources Inc. (2.00%), Farallon Capital Management LLC (1.85%) and Victory Capital Management Inc. (1.63%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Highland Capital Management LP, Royal Bank of Canada, Prudential Financial Inc., Copernicus Capital Management LLC, Candriam Luxembourg S.C.A., Seven Eight Capital LP and Russell Investments Group Ltd.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

FOLD stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BlackRock Inc., Sphera Funds Management LTD., Redmile Group LLC, Farallon Capital Management LLC, Victory Capital Management Inc., Loomis Sayles & Co. L P and Delek Group Ltd.. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FOLD stock can currently be purchased for approximately $15.81.

Amicus Therapeutics has a market capitalization of $3.22 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]